The Australian medical community is buzzing with the introduction of retatrutide, a novel dual GIP and GLP-1 receptor agonist showing remarkable results in early trials for managing obesity. This medication https://icelisting.com/story23077198/the-new-retatrutide-australia-a-emerging-prospect-for-weight-management